Deliberazione
Autorizzazione allo studio clinico sperimentale, farmacologico, profit, denominato: “A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjögren’s syndrome” - Codice Protocollo CVAY736A2302
N° 514
del 28/10/2022








